StockWatch
·

LINCOLN PHARMACEUTICALS LTD.

BSE: 531633

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
200.88
-0.3%+17.8%
Expenditure
171.86
+11.6%+21.2%
Net Profit
20.43
-43.6%+2.2%
OPM %
12.38%
-3.09pp-3.19pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0056.43112.87169.30225.73Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Lincoln Pharma Q2 FY27: PAT up 2% YoY as margins compress, revenue +17%

pharmaceuticals · margin compression · profit growth lag

ResultsQ2 FY2729 Oct 20263 minPharma & Healthcare

Lincoln Pharma Q1FY27: consolidated PAT up 31% YoY to ₹36.2 Cr as revenue rises 15%

pharmaceuticals · export expansion · other income growth

ResultsQ1 FY2713 Aug 20263 minPharma & Healthcare
Latest
Quarterly Result29 Oct, 12:22 pm

Lincoln Pharma Q2 FY27: PAT up 2% YoY as margins compress, revenue +17%

Lincoln Pharmaceuticals reported consolidated (and effectively identical standalone) revenue from operations of ₹191.35 Cr for Q2 FY27, up 17.1% YoY from ₹163.36 Cr and up 7.9% QoQ from ₹177.28 Cr in Q1 FY27. Profit did not keep pace: consolidated PAT was ₹20.43 Cr, up just 2.2% YoY from ₹19.98 Cr, and down 43.6% QoQ from ₹36.23 Cr in Q1 FY27. EPS was ₹10.20 against ₹9.98 a year earlier. Neither period carried exceptional items, so this is a clean like-for-like reported comparison, not a one-off distortion. The gap between revenue and profit growth shows up in margins. Operating margin (PBT + finance cost + depreciation, less other income, over revenue from operations) fell to roughly 12.4% from about 15.5% both a year ago and last quarter, while net profit margin on total income slipped to 10.2% from 17.98% in Q1 FY27 and 11.71% in Q2 FY26. Total expenses rose faster than income this quarter, with cost of materials consumed the single largest line at ₹77.47 Cr. Tax of ₹8.59 Cr included a ₹1.74 Cr short provision for prior years, a modest additional drag on reported PAT but not the main story — the main story is expense growth outrunning revenue growth. No street estimates could be found for this print: a pre-result preview explicitly noted that no analyst consensus for Lincoln Pharma's Q2 FY27 was in the public domain, so vsStreet is unknown rather than inferred. The company also has no formal prior guidance on record for this specific quarter, so the print cannot be graded against a stated target; alongside results it reiterated a three-year ambition of ₹1,000 Cr revenue at 15-18% annual growth led by cardiac, diabetic, dermatology and ENT segments — a forward target, not a backward-looking guidance score. During the quarter the company launched four new domestic divisions and commissioned an API facility at its Khatraj plant, closed its trading window ahead of results, saw its senior QA General Manager resign (with a replacement appointed the same week), held its 32nd AGM approving an FY26 final dividend of ₹1.80/share, and saw FII holding rise to 4.55% as of September 30, 2026 — none of which directly explains the margin compression, which traces to the expense-side numbers above. Management's press release framed the quarter as "another strong quarter, reflecting our focus on sustainable growth," a framing that holds on the topline (+17.75% YoY per the release's total income figure) but sits uneasily against 2% YoY PAT growth and sequential margin compression visible in the filed statements; the release's own EBITDA growth figure of 1.71% YoY (₹33.22 Cr vs ₹32.66 Cr) is consistent with the margin pressure flagged here, even though the accompanying commentary emphasizes growth over margin.

29 Oct 2026, 12:22 pm

Corporate Events

Board MeetingLINCOLN
2026
29Oct

Board Meeting

To consider and approve un-audited financial results (standa…

BSE Filing ↗
Board MeetingLINCOLN
2026
30Sep

Board Meeting

The 32nd Annual General Meeting of the Company is scheduled …

BSE Filing ↗
DividendLINCOLN
2026
12Sep

₹1.8 / share

BSE Filing ↗
Board MeetingLINCOLN
2026
13Aug

Board Meeting

The meeting of the Board of Directors of the Company is sche…

BSE Filing ↗
Board MeetingLINCOLN
2026
28May

Board Meeting

The board meeting is scheduled to consider and approve the a…

BSE Filing ↗
Board MeetingLINCOLN
2026
12Feb

Board Meeting

Consider and approve unaudited Financial Results

BSE Filing ↗
Board MeetingLINCOLN
2025
13Nov

Board Meeting

considering and approving un-audited financial results, any …

BSE Filing ↗
DividendLINCOLN
2025
30Sep

₹1.8 / share

BSE Filing ↗
Board MeetingLINCOLN
2025
7Aug

Board Meeting

considering and approving unaudited financial results, any o…

BSE Filing ↗
Board MeetingLINCOLN
2025
22May

Board Meeting

Consider and approve the audited (standalone and consolidate…

BSE Filing ↗
Board MeetingLINCOLN
2025
13Feb

Board Meeting

Consider and approve unaudited Financial Results

BSE Filing ↗
Board MeetingLINCOLN
2024
14Nov

Board Meeting

Consider and approve un-audited financial results (standalon…

BSE Filing ↗
DividendLINCOLN
2024
30Sep

₹1.8 / share

BSE Filing ↗
DividendLINCOLN
2024
16May

₹1.8 / share

BSE Filing ↗
Board MeetingLINCOLN
2024
16May

Board Meeting

Consider and approve Audited (standalone and consolidated) f…

BSE Filing ↗
Board MeetingLINCOLN
2024
8Feb

Board Meeting

To consider and approve un-audited financial results (standa…

BSE Filing ↗
Board MeetingLINCOLN
2023
2Nov

Board Meeting

To consider and approve un-audited financial results (standa…

BSE Filing ↗